YU22693A - Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije - Google Patents

Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije

Info

Publication number
YU22693A
YU22693A YU22693A YU22693A YU22693A YU 22693 A YU22693 A YU 22693A YU 22693 A YU22693 A YU 22693A YU 22693 A YU22693 A YU 22693A YU 22693 A YU22693 A YU 22693A
Authority
YU
Yugoslavia
Prior art keywords
hiv
recombinant human
infection
antitles
prevention
Prior art date
Application number
YU22693A
Other languages
English (en)
Inventor
A.E. Emini
J.A. Conley
E.G. Mark
S.L. Johnson
S.D. Pfarr
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU22693A publication Critical patent/YU22693A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REKOMBINANTNA HUMANA MONOKLONALNA ANTITELA KOJA NEUTRALIŠU HIV, opisani su molekuli rekombinatnog humanog imunoglobulina koji neutrališu HIV, postupci za dobijanje imunoglobulina i postupci za sprečavanje HIV-1 infekcije koristeći imunoglobuline. DNK konstrukcije koje sadrže komplementarne determinišuće regiona (CDRe) i rešetke (FRs) prirodnog humanog antitela se kombinuju sa drugim konstantnim regionima i ekspresuju u rekombinatne ćelije domaćina. Ova rekombinanta antitela su korisna za tretiranje i sprecavanje HIV-1 infekcije in vivo.
YU22693A 1992-04-01 1993-04-01 Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije YU22693A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01

Publications (1)

Publication Number Publication Date
YU22693A true YU22693A (sh) 1997-01-08

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
YU22693A YU22693A (sh) 1992-04-01 1993-04-01 Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije

Country Status (19)

Country Link
EP (1) EP0577243A3 (sh)
JP (1) JPH06217791A (sh)
KR (1) KR950700761A (sh)
CN (1) CN1081716A (sh)
AU (2) AU3928593A (sh)
BG (1) BG99074A (sh)
CA (1) CA2093099A1 (sh)
CZ (1) CZ239694A3 (sh)
FI (1) FI944561A0 (sh)
HU (1) HUT70461A (sh)
IL (1) IL105145A0 (sh)
MX (1) MX9301858A (sh)
NO (1) NO943653L (sh)
NZ (1) NZ251582A (sh)
RU (1) RU94045907A (sh)
SK (1) SK116294A3 (sh)
WO (1) WO1993019785A1 (sh)
YU (1) YU22693A (sh)
ZA (1) ZA932308B (sh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916306T2 (de) * 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
MX2017000026A (es) * 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
WO1990015078A1 (en) * 1989-06-05 1990-12-13 Scott Charles F Jr HUMAN MONOCLONAL ANTIBODIES TO HIV-1MN gp 120
WO1991019797A1 (en) * 1990-06-15 1991-12-26 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (en) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
ZA932308B (en) 1994-09-30
EP0577243A3 (en) 1994-11-02
HU9402824D0 (en) 1994-11-28
MX9301858A (es) 1994-03-31
CN1081716A (zh) 1994-02-09
KR950700761A (ko) 1995-02-20
AU3563093A (en) 1993-10-07
HUT70461A (en) 1995-10-30
RU94045907A (ru) 1996-11-10
AU3928593A (en) 1993-11-08
SK116294A3 (en) 1996-11-06
NZ251582A (en) 1997-07-27
CZ239694A3 (en) 1995-07-12
FI944561A (fi) 1994-09-30
EP0577243A2 (en) 1994-01-05
FI944561A0 (fi) 1994-09-30
JPH06217791A (ja) 1994-08-09
NO943653D0 (no) 1994-09-30
IL105145A0 (en) 1993-07-08
WO1993019785A1 (en) 1993-10-14
AU658987B2 (en) 1995-05-04
NO943653L (no) 1994-11-30
CA2093099A1 (en) 1993-10-02
BG99074A (en) 1995-11-30

Similar Documents

Publication Publication Date Title
DE69232539D1 (de) Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
FI924819A0 (fi) Chimaera anti-icam-i-antikroppar foer maenniskobruk, foerfaranden foer deras framstaellning samt deras anvaendning
ATE130765T1 (de) Gentechnologisch veränderte immunglobuline.
DK0528767T3 (da) antistofderivater
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
DK499086D0 (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
ATE403680T1 (de) Herstellung tetravalenter antikörper
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE69233191D1 (de) Cyclin d1 und seine cdna
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
DK113389D0 (da) Monoklonale antistoffer
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DK0500659T3 (da) Monoklonale antistoffer.
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
FI934145A (fi) Omformade monoklonala antikroppar mot en immunoglobulinisotyp
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast